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b-Cell destruction in type 1 diabetes (T1D) is at least in part consequence of a ‘dialog’ between b-cells and
immune system. This dialog may be affected by the individual’s genetic background. We presently evaluated
whether modulation of MDA5 and PTPN2, two candidate genes for T1D, affects b-cell responses to double-
stranded RNA (dsRNA), a by-product of viral replication. These genes were selected following comparison
between known candidate genes for T1D and genes expressed in pancreatic b-cells, as identiﬁed in previous
array analysis. INS-1E cells and primary ﬂuorescence-activated cell sorting-puriﬁed rat b-cells were trans-
fected with small interference RNAs (siRNAs) targeting MDA5 or PTPN2 and subsequently exposed to intra-
cellular synthetic dsRNA (polyinosinic–polycitidilic acid—PIC). Real-time RT–PCR, western blot and viability
assays were performed to characterize gene/protein expression and viability. PIC increased MDA5 and PTPN2
mRNA expression, which was inhibited by the speciﬁc siRNAs. PIC triggered apoptosis in INS-1E and primary
b-cells and this was augmented by PTPN2 knockdown (KD), although inhibition of MDA5 did not modify PIC-
induced apoptosis. In contrast, MDA5 silencing decreased PIC-induced cytokine and chemokine expression,
although inhibition of PTPN2 induced minor or no changes in these inﬂammatory mediators. These ﬁndings
indicate that changes in MDA5 and PTPN2 expression modify b-cell responses to dsRNA. MDA5 regulates
inﬂammatory signals, whereas PTPN2 may function as a defence mechanism against pro-apoptotic signals
generated by dsRNA. These two candidate genes for T1D may thus modulate b-cell apoptosis and/or local
release of inﬂammatory mediators in the course of a viral infection by acting, at least in part, at the pancreatic
b-cell level.
INTRODUCTION
Type 1 diabetes (T1D) is a chronic autoimmune disease with
a strong inﬂammatory component. Islet inﬂammation (insuli-
tis) probably takes place in the context of a ‘dialog’ between
invading immune cells and the target b-cells. This dialog is
partially mediated by cytokines and chemokines released by
both b-cells and immune cells and by immunogenic signals
delivered by dying b-cells. This leads to induction and
ampliﬁcation or, in some cases, resolution of insulitis (1).
The evolution of islet inﬂammation, and its potential pro-
gression to clinical diabetes, probably depends on the inter-
play between the patient’s genetic background and
environmental triggers, such as viral infections and/or diete-
tic components (1–4).
Identiﬁcation of genetic-based pathways for complex dis-
eases, such as T1D, provides the initial framework for inves-
tigations of environmental inﬂuences on a given genetic
background (5). The relevance of this approach has already
been shown in rheumatoid arthritis (6), and was recently con-
ﬁrmed in the context of T1D by a study showing interaction
between polymorphisms in the candidate gene PTPN22 and
the early introduction of cow’s milk in the emergence of
islet autoantibodies and diabetes in a Finnish population (7).
These population studies, however, cannot clarify the molecu-
lar mechanisms involved in the interactions between the
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issue in the context of candidate genes that may affect pan-
creatic b-cell survival and insulitis development in T1D, we
used a three-pronged strategy.
(1) Compare the list of known candidate genes for T1D (8–
12) with genes expressed in pancreatic b-cells and modi-
ﬁed by inﬂammatory cytokines and/or double-stranded
(ds) RNA/virus as determined by our previous microarray
analysis (13–18). We observed that at least 30% of the
candidate genes for T1D are expressed in b-cells (data
not shown), conﬁrming that these cells may have an
active role in the emergence of insulitis (1). Two of the
identiﬁed candidate genes were of particular interest,
namely MDA5 (melanoma differentiation-associated
gene 5; also known as IFIH1) and PTPN2 (protein tyro-
sine phosphatase N2; also known as TC-PTP or
PTP-S2). MDA5 is a cytoplasmic receptor for viral
nucleic acids involved in the innate immune response to
viruses (19). Rare polymorphisms of MDA5, leading to
inhibited function, decrease the risk of T1D by nearly
50% (20). Since MDA5 is a member of the retinoic acid-
inducible gene I (RIG-I)-like receptor (RLR) family, we
investigated in parallel the role of the other helicase,
RIG-I, previously shown to be involved in the recognition
of cytoplasmic 50-triphosphate single-stranded RNA and
double-stranded RNA (dsRNA) (21), and of some of the
key signalling patterns involved in dsRNA-induced
b-cell apoptosis. The phosphatase PTPN2 functions as a
negative regulator of several signalling pathways, includ-
ing Janus kinases (JAKs), signal transducer and activator
of transcription (STATs), p42/44 MAPK (ERK), epider-
mal growth factor receptor and insulin receptor b, and
modulates b-cell apoptosis induced by interferon
(IFN)-g (18);
(2) Design speciﬁc small interference RNAs (siRNAs) target-
ing these genes to evaluate their function in b-cells, with
special focus on the induction of apoptosis and production
of inﬂammatory cytokines and chemokines;
(3) Expose b-cells transfected with siRNAs targeting the can-
didate genes to intracellular double-stranded (ds) RNA.
dsRNA is a by-product generated during replication and
transcription of both RNA and DNA viruses and an efﬁ-
cient inducer of apoptosis, type I interferons and other
cytokines/chemokines important for the host immune
response to viral infection (22,23). We thus aimed to
model in vitro and under well-controlled conditions the
putative genetic/environmental interactions that may take
place in early T1D.
The data obtained suggest that MDA5 and PTPN2 are
induced by dsRNA in pancreatic b-cells. Of interest, blocking
MDA5 expression prevents dsRNA-induced expression of
cytokines and chemokines, important mediators of insulitis.
PTPN2 seems to play a different role in this process, since
PTPN2 silencing sensitized b-cells to dsRNA-induced apopto-
sis but had limited effects on the expression of inﬂammatory
mediators. These observations indicate that two candidate
genes for T1D may act, at least in part, at the b-cell level,
modulating apoptosis and the generation of inﬂammatory
signals in the course of a viral infection.
RESULTS
siRNAs against MDA5 and RIG-I prevent polyinosinic–
polycitidilic acid-induced activation of interferon b/NF-kB
and chemokines, but not apoptosis in insulin-producing
cells
We used the synthetic dsRNA polyinosinic–polycitidilic acid
(PIC) with different lengths (21) to selectively evaluate the
role of MDA5 and RIG-I (Supplementary Material,
Fig. S1A). The largest PIC (.2000 bp; PIC2) preferentially
induced MDA5, whereas the PIC with ,2000 bp (PIC1)
induced mostly RIG-I (data not shown). Both forms of
PIC induced a signiﬁcant increase in apoptosis in INS-1E
cells detected 12 h after exposure [Supplementary Material,
Figs S1B and S2C; there was no increase in apoptosis at 6 h
(data not shown)]. Transfection with respective PICs increased
the expression of MDA5 (Fig. 1A and Supplementary
Material, Fig. S2A) and RIG-I (Fig. 1B) by 23- and 40-fold
after 24 h. To evaluate the functional role of MDA5 and
RIG-I, INS-1E cells were pre-treated either with an inactive
siRNA (siControl) or with siRNAs targeting MDA5
(siMDA5) or RIG-I (siRIG-I). The siControl has been vali-
dated by previous studies from our group (18,24), and a
recent array analysis indicated that it does not modify the
expression of MDA5, RIG-I or other genes related to b-cell
function and survival (unpublished data). PIC-induced
MDA5 or RIG-I expression was prevented by .80% by the
speciﬁc siRNAs against MDA5 or RIG-I, but not by the siCon-
trol (Fig. 1A and B). To further conﬁrm the efﬁciency of these
KDs, we performed reporter assays using an IFN-b promoter
reporter or a reporter containing multiple NF-kB-binding
sites. Both reporters were activated by PIC, and MDA5 KD
partially inhibited their activation (Fig. 1C and D). Similar
results were observed with siRNA-mediated inhibition of
RIG-I, with the difference that siRIG-I did not prevent
NF-kB induction (Supplementary Material, Fig. S3A and B).
We additionally studied the effect of knocking down these
helicases in PIC-induced apoptosis. Both PICs induced apop-
tosis, but neither MDA5 nor RIG-I silencing prevented cell
death 24 h after PIC transfection (Fig. 1E and F). To
exclude that this absence of protection was due to redundancy
between the two helicases (i.e. MDA5 would compensate for
the absence of RIG-I in the recognition of dsRNA and vice
versa), we performed double-KD of MDA5 and RIG-I but
this also failed to prevent PIC-induced apoptosis (data not
shown). This suggests that both helicases are not crucial reg-
ulators of intracellular PIC-induced b-cell death.
One of the mechanism by which viruses may contribute to
T1D is by promoting the expression of pro-inﬂammatory
mediators (1,25). Against this background, we next examined
the effect of MDA5 and RIG-I KD on PIC-induced expression
of cytokines and chemokines in INS-1E cells. There was a
marked induction of the expression of mRNAs encoding for
the cytokines IFN-b and interleukin (IL) 15 and the chemo-
kines CCL2, CCL5 and CXCL10 after 24 h of PIC exposure
compared with untreated cells (Fig. 2A and B). MDA5 KD
signiﬁcantly reduced PIC-induced expression of all cytokines
and chemokines studied, whereas RIG-I KD decreased
PIC-induced expression of IFN-b, CCL2 and CXCL10, but
not IL15 or CCL5 (Fig. 2B). A similar pattern was observed
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conﬁrmed by the use of a second siRNA against MDA5 (Sup-
plementary Material, Fig. S4).
Primary b-cells, different from INS-1E cells, express an
additional receptor for dsRNA, namely the toll-like receptor
3 (TLR3) (26), potentially creating a more complex response
to dsRNA. Similar to INS-1E cells, PIC induced a marked
increase of MDA5 and RIG-I expression in primary b-cells.
siMDA5 and siRIG-I prevented PIC-induced MDA5 and
RIG-I mRNA expression by .80% (Fig. 4A and B). In
line with the observations made in INS-1E cells, KD of
both helicases did not modify b-cells apoptosis after PIC
exposure (Fig. 4C and D). Expression of mRNAs encoding
for IFN-b, IL15, CCL2, CCL5 and CXCL10 was also
induced in b-cells, and this was partially prevented by KD
of MDA5, except for IL15 (Fig. 4E). On the other hand,
RIG-I KD failed to prevent PIC-induced expression of the
cytokines and chemokines studied (Fig. 4F). These ﬁndings
were conﬁrmed at the protein level for the chemokine
CCL5 (Supplementary Material, Fig. S5A and B), and as
whole they suggest that MDA5 plays a more important role
than RIG-I for the recognition of intracellular dsRNA in
b-cells.
Mechanisms contributing for PIC-induced apoptosis
in insulin-producing cells
Since KD of the helicases MDA5 and RIG-I failed to prevent
b-cell apoptosis induced by intracellular dsRNA (Figs 1 and
4), we next examined the putative role of the dsRNA-
dependent protein kinase (PKR) in this process. PKR was pre-
viously shown to contribute for external dsRNAþ-
IFN-g-induced apoptosis in mouse islet cells (27). PIC
induced a 20-fold increase in PKR expression, which was
prevented by .80% using a speciﬁc siRNA against PKR
(Supplementary Material, Fig. S6A). PKR KD, however, did
not prevent PIC-induced apoptosis (Supplementary Material,
Fig. S6B) or the induction of cytokines or chemokines (Sup-
plementary Material, Fig. S6C) in primary b-cells. Unexpect-
edly, PKR KD augmented PIC-induced CCL2 expression
(Supplementary Material, Fig. S5C).
These, and our previous observations, suggest that the
pattern recognition receptors TLR3 (28), MDA5, RIG-I and
PKR (present data) are not the main mediators of internal
dsRNA-induced b-cell apoptosis. Of note, we have previously
shown that TLR-3 plays a key role for b-cell apoptosis
triggered by external PICþIFN-g (26). To further clarify
Figure 1. siMDA5 and siRIG-I prevent PIC-induced activation of interferon-b promoter and NF-kB reporter, but do not modify INS-1E cell death. INS-1E cells
were transfected with either an siControl (black bars), or siMDA5 (grey bars) or siRIG-I (striped bars). After 24 h of recovery, cells were left untreated or trans-
fected with PIC1 (,2000 bp, used for siRIG-I experiments) or PIC2 (.2000 bp, siMDA5 experiments) as described in Materials and Methods. (A and B) MDA5
and RIG-I mRNA expression was assayed by real-time RT–PCR and corrected for the housekeeping gene GAPDH. Results are mean+SEM of three to four
independent experiments;  P , 0.01 versus siControl;   P , 0.01 versus siControlþPIC; ANOVA. (C and D) Twenty-four hours after transfection with
siMDA5, cells were transfected with IFN-b (C) or NF-kB (D) reporters plus a pRL-CMV plasmid (used as internal control); cells were then exposed to internal
PIC for 24 h and luciferase activity was assayed. The values were corrected for the activity of the internal control, pRL-CMV, and are presented as fold induction
in relation to siControl. Results are mean+SEM of 5–11 independent experiments;  P , 0.05 versus siControl,   P , 0.05 versus siControlþPIC, paired t-test.
(E and F) INS-1E cells were transfected with siMDA5 or siRIG-I and then PIC as described earlier. Apoptosis was evaluated using HO/PI staining. Results are
mean+SEM of ﬁve independent experiments;  P , 0.01 versus siControl; ANOVA.
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apoptosis, we next examined the downstream apoptosis regu-
lators Jun N-terminal kinase (JNK)/JunB (29). PIC transfec-
tion induced concomitant JNK phosphorylation and
decreased JunB protein expression (Fig. 5A and B). To inves-
tigate whether the decline in JunB expression was secondary
to JNK activation, as previously shown in other experimental
models (30), we used the JNK inhibitor SP600125. SP600125
decreased PIC-induced JNK phosphorylation and prevented
PIC-induced decline in JunB protein expression (Fig. 5C).
We have previously observed a similar phenomenon in
b-cells treated with cytokines (29), suggesting that JunB
degradation is indeed secondary to JNK activation in b-cells.
JNK activation is one of the mechanisms by which dsRNA
induces apoptosis in other cell types (31). In line with these
observations, two different JNK inhibitors, namely the chemi-
cal inhibitor SP600125 and the D-TAT JNKi peptide (32),
induced a partial protection against PIC-induced apoptosis in
INS-1E cells (Fig. 5D and E). JunB reduces cytokine-mediated
endoplasmic reticulum (ER) stress and prevents apoptosis in
pancreatic b-cells (29); since one of the effects of JNK acti-
vation is to reduce JunB protein levels (Fig. 5B and C), we
next examined whether decreased JunB expression indeed
contributes for PIC-induced apoptosis. For this purpose,
JunB was knocked down by the use of a speciﬁc and pre-
viously validated siRNA (29). KD of JunB (Fig. 6A and B)
Figure 2. MDA5 or RIG-I KD partially prevents PIC-induced upregulation of mRNA expression of cytokines and chemokines in INS-1E cells. INS-1E cells
were transfected with siControl (black bars), siMDA5 (grey bars) or siRIG-I (striped bars), and after recovery left untreated or exposed to different internal PICs
(PIC1 for siRIG-I experiments and PIC2 for siMDA5 experiments) for 24 h. Poly(A)þ mRNA was extracted, assayed by real-time RT–PCR for rat IFN-b, IL15,
CCL2, CCL5 and CXCL10 mRNAs and corrected for the housekeeping gene GAPDH. Results are mean+SEM of three to four independent experiments;  P ,
0.05 versus siControl,   P , 0.01 versus siControl,    P , 0.01 versus siControlþPIC, ANOVA.
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Fig. S7) and aggravated PIC-induced apoptosis in both
INS-1E cells and autoﬂuorescence-activated cell sorting
(FACS)-puriﬁed b-cells (Fig. 6C and D). These results were
conﬁrmed with a second siRNA against JunB (data not
shown). To determine whether increase in cell death was
NO- and ER stress dependent, we evaluated the mRNA
expression of XBP1s, CHOP and iNOS, and nitrite production.
There was no difference between expression of these markers
in cells treated with siJunB or siControl plus PIC (data not
shown), suggesting that JunB protects b-cells against
PIC-induced apoptosis by an ER stress- and NO-independent
mechanism that remains to be clariﬁed.
JunB is one of the subunits of the transcription factor acti-
vator protein-1 (AP-1). Besides its role in the process of apop-
tosis, AP-1 also regulates the expression of cytokines and
chemokines in other cell types (33). We did not, however,
observe any effect of JunB KD on PIC-induced expression
of cytokines and chemokines (Supplementary Material,
Fig. S8).
PTPN2 modulates PIC-induced b-cell apoptosis
PIC induced expression of PTPN2 at both mRNA and protein
levels in INS-1E cells and FACS-puriﬁed rat b-cells (Fig. 7 A,
B and E). The upregulation of PTPN2 mRNA was signiﬁcant
after 6 h of PIC transfection and remained increased up to 24 h
(Supplementary Material, Fig. S2B). A previously validated
siRNA against PTPN2 (18) decreased its basal mRNA
expression by .60 and .80% in INS-1E and primary
b-cells, respectively, and blocked PTPN2 induction after
PIC exposure in both cell types (Fig. 7A and B). Of relevance,
PTPN2 KD sensitized INS-1E cells (Fig. 7C and F) and
primary b-cells (Fig. 7D) to PIC-induced apoptosis, indicating
a potential modulatory function for this candidate gene in
b-cell death during viral infection. On the other hand,
PTPN2 had no or mild effect on the expression of chemokines
and cytokines following transfection with PIC (Supplementary
Material, Fig. S9). These results were conﬁrmed with a second
siRNA against PTPN2 (data not shown).
DISCUSSION
We presently show that two candidate genes for T1D, namely
MDA5 and PTPN2, modulate b-cell responses to dsRNA, a
by-product of viral infection. The ﬁndings suggest that
MDA5 controls the local expression of cytokines and chemo-
kines during a viral infection, whereas PTPN2 might protect
b-cells from virus-induced apoptosis.
Viruses are one of the putative environmental factors
associated with T1D in genetically susceptible individuals
(1,2). As the ﬁrst line of defence against pathogens, non-
immune cells (present data) and cells from the innate
immune system detect viral infections by pattern-recognition
receptors (PRRs) that identify pathogen-associated molecular
patterns, such as dsRNAs. Both RNA and DNA viruses
produce dsRNA as an intermediate product of their replica-
tion. Human and rodent pancreatic islets express PRRs for
dsRNA, namely TLR3, RIG-I and MDA5 (17,26,34,35;
present data). Studies in knockout animals demonstrated that
the helicases RIG-I and MDA5 recognize different types of
viruses, with MDA5 acting as the main receptor for cyto-
plasmic dsRNA in astrocytes (36) and b-cells (present data).
Of particular relevance in the context of T1D, MDA5 recog-
nizes members of the picornavirus family, including Coxsack-
ievirus B4, Encephalomyocarditis virus and Theiler’s virus
(37). Coxsackievirus B4 was recently isolated from the pan-
creas of patients with new onset T1D (38,39), and polymorph-
isms leading to loss of function of MDA5 confer resistance
against T1D (20).
To study the mechanisms by which changes in MDA5 func-
tion may contribute to insulitis and b-cell apoptosis, we com-
bined the use of siRNA-mediated inhibition of MDA5 with
transfection of b-cells with synthetic dsRNA (PIC). Decrease
in the expression of MDA5 or the related helicase RIG-I did
not protect b-cells against PIC-induced apoptosis, but KD of
MDA5 inhibited expression of the inﬂammatory mediators
CXCL10, CCL2, CCL5, IFN-b and IL15. The chemokine
CXCL10 attracts monocytes, T lymphocytes and natural killer
(NK) cells (40), and islet-speciﬁc expression of CXCL10 in a
mouse model of autoimmune diabetes caused by viruses [rat
insulin promotor (RIP)-LMCV] accelerates autoimmunity by
enhancing the migration of antigen-speciﬁc lymphocytes (41).
On the other hand, neutralization of CXCL10 (42) or its recep-
tor (CXCR3) (43) prevents autoimmune disease in the same
mouse model (RIP-LCMV). CCL2 attracts monocytes and T
lymphocytes and may thus contribute to the migration of
mononuclear cells to pancreatic islets in early T1D (44).
CCL5 attracts activated T-cells, dendritic cells and monocytes
during inﬂammation and early immune responses (45). Individ-
uals with speciﬁc polymorphisms in this gene present lower
Figure 3. MDA5 but not RIG-I KD prevents PIC-induced CCL5 secretion in
INS-1E cells. INS-1E cells were transfected with siControl (black bars),
siMDA5 (A, grey bars) or siRIG-I (B, striped bars) and then treated as
described in Figure 2. CCL5 secretion was evaluated in the supernatant by
ELISA 24 h after internal PIC exposure (PIC1 for siRIG-I experiments and
PIC2 for siMDA5 experiments), as described in Materials and Methods.
Results are mean+SEM of three to four independent experiments;  P ,
0.01 versus siControl,   P , 0.01 versus siControlþPIC, ANOVA.
Human Molecular Genetics, 2010, Vol. 19, No. 1 139Figure 4. siMDA5 or siRIG-I prevent PIC-induced upregulation of cytokines and chemokines, but not apoptosis, in primary rat b-cells. FACS-puriﬁed rat b-cells
were transfected with siControl (black bars), siMDA5 (grey bars) or siRIG-I (striped bars) as described in Materials and Methods. After 48 h of recovery, cells
were left untreated or transfected with different PICs (PIC1 for siRIG-I experiments and PIC2 for siMDA5 experiments) for 24 h. (A and B) MDA5 and RIG-I
mRNA expression was assayed by real-time RT–PCR and corrected for the housekeeping gene GAPDH. Results are mean+SEM of four to six independent
experiments;  P , 0.01 versus siControl;   P , 0.01 versus siControlþPIC, ANOVA. (C and D) Apoptosis was evaluated 24 h after PIC exposure using HO/PI
staining. Results are mean+SEM of three to ﬁve independent experiments;  P , 0.01 versus siControl, ANOVA. (E and F) INF-b, IL15, CCL2, CCL5 and
CXCL10 mRNA expression were assayed by real-time RT–PCR and corrected for the housekeeping gene GAPDH. Results are mean+SEM of four to six
independent experiments;  P , 0.01 versus siControl;   P , 0.01 versus siControlþPIC, ANOVA.
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IL15 enhances the cytolytic function of T and NK cells and
induces IFN-g production by NK cells; it also functions as a
potent growth factor of T-, B-, and NK cells (47). Studies in
NOD mice have demonstrated elevated expression of
CXCL10, CCL2 and IL15 mRNAs and/or protein in pancreatic
islets during the prediabetic stage (1,48,49). The type I inter-
feron IFN-b is a cytokine produced by most cells during viral
infections, promoting the expression of diverse genes relevant
for the antiviral response in target cells; and it also modulates
the adaptive immune system by activating dendritic cells, T-
and B-cells (23,50). Of relevance, type I IFNs have been
detected in the islets of patients with recent onset T1D
(51,52), and transgenic expression of IFN-b in mouse b-cells
leads to diabetes (53). The present observation that MDA5
modulates dsRNA-induced expression of these cytokines and
chemokines in INS-1E cells and primary b-cells reinforces
thehypothesisthatthiscandidategenehasakeyroleintheregu-
lation of local islet inﬂammation during viral infection.
Since there was no protection against PIC-induced apoptosis
after MDA5 and/or RIG-I KD in our model, we searched for
alternative pathways that may explain the pro-apoptotic
effects of intracellular PIC in b-cells. The main ﬁnding was
that JNK, an activator of the transcription factor AP-1, contrib-
utes for apoptosis after PIC transfection, an effect mediated at
least in part via JunB protein degradation. The role of JNK acti-
vation in PIC-induced apoptosis has been shown previously in
HeLa cells (31), but to our knowledge there are no previous
reports on the putative role for JunB degradation on this
process. JunB degradation also plays a role in cytokine-induced
b-cell apoptosis (29), emphasizing the relevant role of JunB in
preserving b-cell viability. In the case of cytokine-triggered
apoptosis, however, part of the protective effects of JunB are
due to inhibition of NO formation and induction of ER stress
(29). NO and ER stress do not play a major role for intracellular
PIC-induced b-cell death (data not shown), suggesting that
JunB acts by another mechanism in this context. The nature
of this mechanism remains to be clariﬁed.
As mentioned earlier, type IIFNsare important cytokines for
the host immune response against viral infections (23). In
addition to antiviral properties, these cytokines have the poten-
tial to induce apoptosis and/or promote systemic autoimmunity
(50). To limit these effects of IFNs, organisms have developed
several negative regulators of the IFN responses (54). One of
these regulators is the phosphatase PTPN2, which prevents sus-
tained IFN signalling by dephosphorylating JAKs and STATs
(55). We have recently shown that KD of PTPN2 in pancreatic
b-cells exposed to IFN-g augments STAT1 signalling and
increases apoptosis (18). In line with these ﬁndings, STAT1
knockout prevents both IL-1bþIFN-g (56) and external
dsRNA plus IFN-g-induced apoptosis in b-cells (26) and
abolishesthe pro-apoptoticeffect ofPTPN2KD inthe presence
of IFN-g (18). We presently demonstrate that, similar to cyto-
kines, PTPN2 KD exacerbates dsRNA-induced apoptosis,
suggesting a potential interaction between an environmental
agent (dsRNA, a viral by product) and a candidate gene for
T1D (PTPN2). This type of interaction may explain why viral
infections only cause diabetes in some individuals or mouse
strains that overreact to the viral challenge. In line with this
hypothesis, PIC only induces diabetes in C57BL/6 mice when
Figure 5. Inhibition of JNK activation partially prevents PIC-induced JunB degradation and apoptosis in INS-1E cells. INS-1E cells were transfected with PIC1
for the indicated time points. (A and B) Expression of phospho-JNK, JunB and a-tubulin were evaluated by western blot. Pictures are representative of three
independent experiments. (C) INS-1E cells were pre-treated with 10 mM of the JNK inhibitor SP600125 for 4 h and then transfected with PIC before being
retrieved for protein extraction at the indicated time points; SP600125 was maintained in the medium following PIC treatment. Phospho-JNK, JunB and
a-tubulin protein were evaluated by western blot. Pictures are representative of three independent experiments. (D and E) INS-1E cells were treated with
the JNK chemical inhibitor SP600125 (D) or the JNK peptide inhibitor (E) for 4 h, and then transfected with PIC plus SP600125 or JNK peptide inhibitor.
Apoptosis was evaluated 24 h after PIC exposure using HO/PI staining. Results are mean+SEM of four independent experiments;  P , 0.05 versus siControlþ
PIC, paired t-test.
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co-stimulatory molecule B7.1 in the islets (57). The B7.1
mice produce higher levels of type I IFNs than wt C57BL/6,
and administration of an antibody against type I IFN prevents
diabetes (57). The protective effects of PTPN2 against
PIC-induced apoptosis seems, however, to be transitory or
insufﬁcient, since 12 h after PIC transfection b-cells start to
die independent of the continuous increase in PTPN2
expression. These results are in line with previous studies
showingthatcytokine-induced increaseinprotective molecules
such as SOCS-3 (58) or JunB (29) is not sufﬁcient to prevent
b-cell death induced by protracted pro-apoptotic stimulus.
MDA5 and PTPN2 are expressed also in other tissues,
including in cells from the immune system (18,19). T1D is a
chronic autoimmune disease in which macrophages, NK and
T-cells play a crucial role in disease development (1). Thus,
different levels of MDA5 and PTPN2 expression in immune
cells may also play a role in the triggering and progression
of insulitis. The relative contribution of candidate gene
expression in immune cells or b-cells needs to be clariﬁed
by future studies using tissue-speciﬁc knockout models.
In conclusion, we demonstrate that two candidate genes for
T1D, namely MDA5 and PTPN2, may contribute to the patho-
genesis of diabetes by modifying the b-cell responses to a viral
infection. MDA5 potentially modulates the cross-talk between
b-cells and the innate/adaptive immune system through the
local production of cytokines and chemokines, whereas
PTPN2 may protect b-cells against apoptosis due to negative
feedback on IFN signalling. Single or, most probably, com-
bined genetically determined changes in the expression of
these and other relevant genes in b-cells and the immune
system may lead to an ‘unlucky genetic combination’, which
causes, for instance, an exaggerated inﬂammatory response
to a b-cell viral infection. If this response is coupled to defec-
tive b-cell protective mechanisms, it may result in excessive
and/or protracted b-cell death, leading to ampliﬁcation of
insulitis and eventually causing enough destruction of
b-cells to trigger clinical diabetes.
MATERIALS AND METHODS
Culture of primary FACS-puriﬁed rat b-cells
and INS-1E cells
Male Wistar rats (Charles River Laboratories, Brussels,
Belgium) were housed and used according to the guidelines
of the Belgian Regulations for Animal Care. Rat islets were
isolated by collagenase digestion followed by hand-picking
under a stereomicroscope. For b-cell isolation, islets were dis-
persed and b-cells puriﬁed by FACS (FACSAria, BD Bio-
science, San Jose, CA, USA) (26,59). The preparations used
in the present study contained 89.4+1.2% b-cells (n ¼ 22).
Puriﬁed b-cells were cultured for 2 days in Ham’s F-10
medium containing 10 mM glucose, 2 mM glutamine, 50 mM
3-isobutyl-L-methylxanthine, 5% heat-inactivated fetal
bovine serum (FBS), 0.5% charcoal-absorbed bovine serum
albumin (BSA Fraction V, Boehringer, Indianapolis, IN,
USA), 50 U/ml penicillin and 50 mg/ml streptomycin before
use in subsequent experiments (26,60). During dsRNA and
siRNAs transfection, cells were cultured in the same
medium but without antibiotics or BSA.
The rat insulin-producing INS-1E cell line (a kind gift from
Dr C. Wollheim, Centre Medical Universitaire, Geneva,
Switzerland) was cultured in RPMI 1640 GlutaMAX-I, 5%
FBS, 10 mM HEPES, 1 mM Na-pyruvate and 50 mM
2-mercaptoethanol (61). INS-1E cells (passages 57–75) were
plated for 48 h prior to transfection.
RNA interference
The following siRNAs were used in this study: Allstars
Negative Control siRNA (Qiagen, Venlo, Netherlands),
Figure 6. JunB KD augments PIC-induced b-cell death. INS-1E cells (A–C) and primary rat b-cells (D) were transfected with siControl, siJunB 1 or siJunB 2
and then treated as described in Figures 2 and 4. (A) JunB protein expression was evaluated after transfection with two speciﬁc siRNAs. Pictures are representa-
tive of three independent experiments. (B) PIC-induced JunB mRNA expression was blocked by siRNA against JunB. Results are mean+SEM of three to four
independent experiments;  P , 0.01 versus siControl,   P , 0.01 versus siControlþPIC, ANOVA. (C and D) Apoptosis was evaluated in INS-1E cells (C) or
FACS-puriﬁed rat b-cells (D) 24 h after PIC exposure using HO/PI staining. Results are mean+SEM of four to six independent experiments;  P , 0.01 versus
siControl,   P , 0.01 versus siControlþPIC, ANOVA.
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w (siMDA5 1;
Thermo Scientiﬁc, Chicago, IL, USA), Silencer
w Select Pre-
designed siRNA rat MDA5 (siMDA5 2; Applied Biosystems,
Austin, TX, USA), Silencer
w Select Custom Designed siRNA
rat RIG-I (Applied Biosystems), ON-TARGETplus rat PTPN2
SMARTpool
w (Thermo Scientiﬁc), Silencer
w Select Pre-
designed siRNA rat PTPN2 (Applied Biosystems), rat JunB
1 and rat JunB 2 (Invitrogen, Carlsbad, CA, USA) and
ON-TARGETplus rat PKR SMARTpool
w (Thermo Scientiﬁc)
(sequences are provided in Supplementary Material,
Table S1). The optimal settings for the transfection of
siRNAs in both INS-1E cells and primary FACS-puriﬁed rat
b-cells were ﬁrst established by using an FITC-coupled
siRNA (siGLO Green Transfection Indicator, Thermo Scienti-
ﬁc), and the transfection procedure performed using
DharmaFECT 1 (Thermo Scientiﬁc) as described (18). The
concentration of 30 nM was selected after dose–response
studies (18; data not shown). Afterwards, cells were cultured
for a 24–48 h recovery period and subsequently transfected
with the synthetic dsRNA, PIC, as described in the following.
dsRNA transfection and JNK inhibition
The synthetic dsRNAs, PIC, were from Sigma-Aldrich (PIC1;
St Louis, MO, USA) and Invivogen (PIC2; San Diego, CA,
USA) and used at the ﬁnal concentration of 1 mg/ml (28).
All experiments were performed with intracellular PIC,
obtained via cell transfection. For PIC transfection, the same
conditions described for siRNA were utilized, except that
the DharmaFECT:PIC ratio used was 0.8 and 1.25 ml of Dhar-
maFECT to 5 mg of PIC for INS-1E cells and primary b-cells,
respectively. Since it was demonstrated that helicases recog-
nize dsRNA molecules on the basis of their length (21), a
PIC with .2000 bp (PIC2) was used for experiments targeting
MDA5, whereas all other experiments were done with PIC1,
with ,2000 bp, as in our previous studies (26,28).
The JNK inhibitor SP600125 (Sigma-Aldrich) was dis-
solved in DMSO and used at a concentration of 10 mM (24).
The peptide JNK inhibitor D-TAT-JNKi (a kind gift of
C. Bonny and M. Mathieu; XigenPharma, Lausanne,
Switzerland) and the control peptide D-TAT were dissolved
in culture medium and used at the concentration of 10 mM
(32). Both inhibitors were added to the cell culture 4 h
before PIC transfection and kept in the medium during PIC
exposure.
Assessment of cell viability
The percentage of viable, apoptotic and necrotic cells was
determined following 15 min of incubation with the DNA-
binding dyes propidium iodide (PI, 5 mg/ml, Sigma) and
Hoechst 33342 (HO, 5 mg/ml, Sigma). This method is
Figure 7. KD of PTPN2 sensitizes INS-1E cells and primary b-cells to PIC-induced apoptosis. INS-1E cells (A) or FACS-puriﬁed rat b-cells (B) were trans-
fected with siControl (black bars) or siPTPN2 (grey bars) and 48 h after recovery exposed to PIC1 for 24 h. (A and B) PTPN2 mRNA expression was evaluated
by real-time RT–PCR and corrected for the housekeeping gene GAPDH. Results are mean+SEM of three to ﬁve independent experiments;  P , 0.01 versus
siControl,   P , 0.01 versus siControlþPIC, ANOVA. (C and D) INS-1E cells (C) or primary b-cells (D) were transfected with siControl or siPTPN2 and 48 h
after recovery exposed to internal PIC1 for 24 h. Apoptosis was evaluated using HO/PI staining. Results are mean+SEM of six independent experiments;  P ,
0.01 versus siControl,   P , 0.05 versus siControlþPIC,    P , 0.01 versus siControlþPIC, ANOVA. (E) PTPN2 and a-tubulin protein expression was
assessed by western blot in FACS-puriﬁed rat b-cells exposed to internal PIC1 for 24 h; the picture is representative of two independent experiments. (F)
INS-1E cells were transfected with control siRNA, or with an siRNA targeting PTPN2 as described in Materials and Methods, and 48 h after recovery
exposed to internal PIC1 for 24 h. Cleavage of caspase-3 was observed by western blot. The picture is representative of two independent experiments.
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b-cells and INS-1E cells by systematic comparison with elec-
tron microscopy, caspase-3 activation and DNA laddering
(14,18,24,26,62). A minimum of 500 cells was counted in
each experimental condition. Viability was evaluated by two
independent observers, one of them being unaware of
sample identity. The agreement between ﬁndings obtained
by the two observers was .90%. Results are expressed as per-
centage of apoptosis and were calculated as number of apop-
totic cells/total number of cells   100. In some experiments,
the presence of apoptosis was conﬁrmed by western blot
analysis of activated (cleaved) caspase-3 (see what follows).
mRNA extraction and real-time PCR
Poly(A)þ mRNA was isolated from INS-1E cells and rat
primary b-cells using the Dynabeads mRNA DIRECTTM kit
(Invitrogen, Paisley, UK), and reverse-transcribed as described
previously (14,26,44). The real-time PCR ampliﬁcation reaction
was done as described (26,44), using SYBR Green and com-
pared with a standard curve (63). Expression values were then
corrected for the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and normalized by the
highest value of each experiment considered 1; PIC treatment
does not modify GAPDH expression in insulin-producing
cells (64,65). The primer sequences for rat PTPN2, MDA5,
RIG-I, PKR, INF-b, IL15, CCL2, CCL5, CXCL10, CHOP,
XBP1-s, iNOS, JunB, GAPDH are described in Supplementary
Material, Table S2. The cytokines and chemokines to be studied
were selected on the basis of our previous array analysis (15)
and studies focused (26,28,64,65) as representative of b-cell
inﬂammatory responses to dsRNA.
Promoter studies
A total of 10
5 INS-1E cells were plated in 24-well plates and
transfected with siRNAs against MDA5, RIG-I or control as
described earlier. After 24 h of recovery, plasmid constructs
containing the ﬁreﬂy luciferase gene under the control of
either multiple copies of the NF-kB consensus sequence
(BD Biosciences Clontech, Mountain View, CA USA) or the
mouse IFN-b promoter (66) were transfected using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer instructions. Twelve hours later, cells were
exposed overnight to internal PIC (1 mg/ml). Luciferase activi-
ties were assayed 24 h after PIC treatment using the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI,
USA) (26,65). Test values were corrected for the luciferase
activity of the internal control plasmid, pRL-CMV, and
shown as fold induction compared with siControl.
Assessment of CCL5 protein and nitrite production
After 24 h of PIC transfection, cell supernatants were retrieved
and rat CCL5 was measured by enzyme-linked immunosor-
bent assay (Quantikine ELISA kit, R&D Systems, Minneapo-
lis, MN, USA).
In some experiments, culture supernatants were also col-
lected for nitrite determination (nitrite is a stable product of
nitric oxide oxidation) at OD540nm using the Griess reagent
(67).
Western blot analysis
Cells were washed once with cold PBS and directly lysed with
either Laemmli buffer (25 mM Tris–HCl, pH 6.8, 10% gly-
cerol, 1% SDS, 350 mM 2-mercaptoethanol, 175 mM dithio-
threitol, 0.005% bromophenol blue completed by a protease
inhibitor cocktail—Roche Diagnostics, Vilvoorde, Belgium)
or phospho lysis buffer (1% NP40, 25 mM Hepes, pH 7.8,
150 mM NaCl, 1 mM CaCl2,1m M MgCl2,5 0m M NaF, 1 mM
Na3VO4,1 m M PMSF and protease inhibitor cocktail).
Lysates were then resolved by 8–12% SDS–PAGE and trans-
ferred to a nitrocellulose membrane. Immunoblot analysis was
performed with antibodies targeting PTPN2 (R&D Systems),
JunB, dsRNA-dependent protein kinase (PKR) (Santa Cruz
Biotechnology, CA, USA), phospho-JNK, cleaved caspase-3
(Cell Signaling, Danvers, MA, USA) or a-tubulin (Sigma,
Bornem, Belgium), used as the housekeeping protein. Horse-
radish peroxidase-conjugated donkey anti-rabbit or anti-mouse
IgG was used as a secondary antibody (Lucron Bioproducts,
De Pinte, Belgium). Immunoreactive bands were revealed
using the SuperSignal West Femto chemiluminescent sub-
strate (Thermo Scientiﬁc), detected using an LAS-3000 CCD
camera and quantiﬁed with the Aida Analysis software
(Fujiﬁlm).
Statistical analysis
Data are presented as mean+SEM. Comparisons were per-
formed by two-tailed paired Student’s t-test or by ANOVA,
followed by Student’s t-test with Bonferroni correction as
indicated. A P-value ,0.05 was considered statistically
signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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